I think the key is revenue increase. IRI has been in transition over the last a few years. If you look R & D expenses, 2019 & 2020 were at $17M, and then the expenditure has gone up year by year: 2021 $19M, 2022 $22M and 2023 $23M.
I suppose IRI technical aspect of transition has been completed. That means R & D expenses should be down to previous level at around $17M, hopefully.
IRI has got large number of blue chip clients so it should not materially increase sales & marketing expenses.
Therefore as long as the clients can adopt IRI new cloud based products and IRI's revenue goes up, its EBITDA margin will go up as well.
- Forums
- ASX - By Stock
- IRI
- Ann: FY2023 Trading Update
Ann: FY2023 Trading Update, page-13
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IRI (ASX) to my watchlist
(20min delay)
|
|||||
Last
68.0¢ |
Change
-0.010(1.45%) |
Mkt cap ! $122.3M |
Open | High | Low | Value | Volume |
69.0¢ | 69.0¢ | 68.0¢ | $29.75K | 43.58K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 67.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
68.0¢ | 3556 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 0.690 |
1 | 31581 | 0.680 |
1 | 5000 | 0.675 |
3 | 31492 | 0.670 |
1 | 1314 | 0.665 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 9219 | 1 |
0.705 | 8511 | 1 |
0.740 | 14492 | 1 |
0.750 | 1333 | 1 |
0.760 | 20000 | 1 |
Last trade - 10.04am 21/10/2024 (20 minute delay) ? |
Featured News
IRI (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online